Innovative Bispecific Nanobody Targeting IGF2R and PDCD1 for Comprehensive Cancer Therapy
VHH-P294 is a bispecific, humanized nanobody fusion construct developed to target both insulin like growth factor 2 receptor (IGF2R) and programmed cell death 1 (PDCD1). This novel therapeutic candidate is currently undergoing biological testing and is engineered for enhanced anticancer efficacy by simultaneously modulating two critical pathways in tumor growth and immune suppression. By combining high specificity and modular design, VHH-P294 holds significant promise as an innovative approach for the treatment of cancer, addressing both tumor proliferation and immune evasion. Its dual-targeting mechanism positions it as a potential advancement in the oncology field.
| Candidate | VHH-P294 |
| Target | insulin like growth factor 2 receptor (IGF2R) programmed cell death 1 (PDCD1) |
| Modality | humanized bispecific VHH |
| Indication | Cancer |
Licensing Opportunity
VHH-P294 is available for out-licensing and partnership. We welcome collaboration opportunities with innovative biopharmaceutical enterprises seeking to advance next-generation cancer therapies.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P294 |
Modality
VHH-P294 is designed as a bispecific nanobody fusion protein, assembling two human codon-optimized single-domain antibody fragments: one against cation-independent mannose 6-phosphate receptor and the other against programmed cell death protein 1. Each fragment is fused to modified human IgG1 Fc regions employing knobs-into-holes technology for efficient dimerization and stability. Expressed in human embryonic kidney cells, the nanobody's compact structure ensures superior tissue penetration, increased stability, and reduced immunogenicity. These unique features are especially advantageous for cancer therapy, enabling improved access to solid tumor sites and sustained therapeutic action compared to conventional antibody modalities.
Target
IGF2R and PDCD1 are two pivotal molecular targets in oncology. IGF2R acts as a multifunctional transmembrane receptor involved in intracellular trafficking and modulation of growth factor signaling, while PDCD1 serves as an immune checkpoint receptor on T cells, regulating immune responses. IGF2R is predominantly expressed in various normal and tumor tissues, and its dysregulation has been implicated in cancer progression and metastasis. PDCD1 is mainly found on immune cells within the tumor microenvironment, where it suppresses antitumor immunity. Targeting both IGF2R and PDCD1 allows VHH-P294 to directly inhibit tumor proliferation and simultaneously reinvigorate antitumor immune responses. This dual engagement of IGF2R and PDCD1 positions VHH-P294 as a strategically valuable asset for comprehensive cancer immunotherapy, leveraging state-of-the-art nanobody engineering to address complex oncogenic pathways.
Mechanism of Action
VHH-P294 exerts its therapeutic efficacy through a distinct dual mechanism. By binding IGF2R, it disrupts signaling pathways associated with tumor growth and metastasis, potentially impeding cancer cell proliferation. Concurrently, targeting PDCD1 enables VHH-P294 to function as an immune checkpoint inhibitor while also facilitating PDCD1 degradation, which can restore T cell activity and amplify antitumor immune responses. The bispecific nanobody platform of VHH-P294 not only ensures potent blockade and downregulation of both targets but also offers broad application potential for next-generation modalities, including antibody-drug conjugates and other multi-specific constructs, expanding its therapeutic utility in oncology.
Cancer
Cancer remains one of the most significant health challenges worldwide, with increasing incidence rates across diverse populations. Although current standard therapies include surgery, chemotherapy, radiotherapy, targeted therapies, and immunotherapy, many patients experience resistance, relapse, or limited efficacy due to tumor heterogeneity and immunosuppressive microenvironments. While immune checkpoint inhibitors and targeted agents have revolutionized treatment paradigms for several cancers, there remains a substantial unmet need for more effective, durable, and safer options. VHH-P294, by simultaneously inhibiting IGF2R-mediated tumor signaling and reversing PDCD1-driven immune suppression, represents a promising therapeutic candidate that could potentially overcome current limitations and address resistance mechanisms encountered with single-target regimens.